Fosfomycin exerts a bactericidal effect on proliferating pathogens by preventing the enzymatic synthesis of the bacterial cell wall.
Fosfomax IV Infusion is indicated for the treatment of the following infections in adults and children including neonates:
Fosfomycin exerts a bactericidal effect on proliferating pathogens by preventing the enzymatic synthesis of the bacterial cell wall. Fosfomycin inhibits the first stage of intracellular bacterial cell wall synthesis by blocking peptidoglycan synthesis.
No drug-drug interaction studies have been performed with fosfomycin.
Hypersensitivity to the active substance, fosfomycin, or to any of the excipients.
The most commonly reported adverse reactions during treatment are gastrointestinal disturbances and injection site reactions. Other important adverse reactions include hypokalaemia and/or hypernatraemia.
No clinical data on pregnancies are available. Fosfomax should therefore not be prescribed to pregnant women unless the benefit outweighs the risk. After the administration of Fosfomax, low quantities of fosfomycin were found in human milk. Fosfomax should therefore not be administered during lactation unless the benefit outweighs the risk.
Experience regarding the overdose of fosfomycin is limited. Cases of hypotonia, somnolence, electrolytes disturbances, thrombocytopenia and hypoprothrombinemia have been reported with parenteral use of fosfomycin.
Intracellular antibiotic
Store below 30° C temperature, protect from light & moisture. Keep out of the reach of children. After being mixed with solvent this medicine should be used immediately or stored in a refrigerator (at 2-8°C) protected from light for up to 24 hours.
